Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CJM112 in moderate to severe inflammatory acne
NCT02998671Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2016
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of CJM112 in acne vulgaris (3 arms), sponsored by Novartis. Primary endpoint: Total Inflammatory Facial Lesion Count at Day 85. Started Dec 2016; status: completed.
02
Drugs
CJM112
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT02998671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02998671.